NCT03130985: PREDICT-AF

Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation

Completed Last updated 12 November 2020

What this trial tests

trial in Atrial Fibrillation in 150 participants. Completed in 30 September 2020.

Timeline

12 May 2015

Primary endpoint
6 July 2020

30 September 2020

Quick facts

Lead sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	150
Start date	12 May 2015
Primary completion	6 July 2020
Estimated completion	30 September 2020
Sites	1 location across Netherlands

Conditions studied

• Atrial Fibrillation — all drugs for Atrial Fibrillation →

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — full company profile →

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients undergoing coronary artery bypass grafting (CABG), aortic (valve) or mitral valve surgery are at risk of developing postoperative and new-onset atrial fibrillation (AF), but adequate risk prediction is currently impossible. This study aims to discover tissue and circulating microRNAs and protein biomarkers that may help to unravel the pathophysiological processes underlying AF and are potential tools for risk stratification and prognosis or may become future targets of therapy.

This study will be a single-center cohort study of 150 patients undergoing cardiac surgery, which will constitute the beginning of the follow-up period. Left atrial appendages, whole blood and epicardial mappings will be collected. Patients will be followed for 2 years with regular holter investigations to detect postoperative and new-onset AF.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Extracellular matrix remodeling precedes atrial fibrillation: Results of the PREDICT-AF trial.
   van den Berg NWE, Neefs J, Kawasaki M, Nariswari FA, et al · · 2021 · cited 44× · PMID 34332113 · DOI 10.1016/j.hrthm.2021.07.059
2. Epicardial and endothelial cell activation concurs with extracellular matrix remodeling in atrial fibrillation.
   van den Berg NWE, Kawasaki M, Fabrizi B, Nariswari FA, et al · · 2021 · cited 30× · PMID 34841686 · DOI 10.1002/ctm2.558
3. Atrial epicardial adipose tissue abundantly secretes myeloperoxidase and activates atrial fibroblasts in patients with atrial fibrillation.
   Meulendijks ER, Al-Shama RFM, Kawasaki M, Fabrizi B, et al · · 2023 · cited 26× · PMID 37280612 · DOI 10.1186/s12967-023-04231-2
4. Absence of Functional Na_v1.8 Channels in Non-diseased Atrial and Ventricular Cardiomyocytes.
   Casini S, Marchal GA, Kawasaki M, Nariswari FA, et al · · 2019 · cited 25× · PMID 31916131 · DOI 10.1007/s10557-019-06925-6
5. Neutrophil degranulation interconnects over-represented biological processes in atrial fibrillation.
   Kawasaki M, Meulendijks ER, van den Berg NWE, Nariswari FA, et al · · 2021 · cited 18× · PMID 33536523 · DOI 10.1038/s41598-021-82533-5
6. PREventive left atrial appenDage resection for the predICtion of fuTure atrial fibrillation: design of the PREDICT AF study.
   van den Berg NWE, Neefs J, Berger WR, Boersma LVA, et al · · 2019 · cited 11× · PMID 31567634 · DOI 10.2459/jcm.0000000000000868
7. MicroRNAs in atrial fibrillation target genes in structural remodelling.
   van den Berg NWE, Kawasaki M, Nariswari FA, Fabrizi B, et al · · 2023 · cited 9× · PMID 37833432 · DOI 10.1007/s00441-023-03823-0
8. microRNAs as Biomarkers of Endothelial Dysfunction and Therapeutic Target in the Pathogenesis of Atrial Fibrillation.
   Desantis V, Potenza MA, Sgarra L, Nacci C, et al · · 2023 · cited 9× · PMID 36982382 · DOI 10.3390/ijms24065307